Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

ABSTRACT:

Background

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes.

Methods

We conducted a phase 3 trial involving children with newly diagnosed standard-risk B-cell ALL who had an average or higher risk of relapse. Patients were randomly assigned to receive chemotherapy alone or chemotherapy plus two nonsequential 28-day cycles of blinatumomab. The primary end point was disease-fr

SUBMITTER: Gupta S 

PROVIDER: S-EPMC11864901 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature